The Japanese guidelines for colorectal cancer treatment and the NCCN clinical practice guidelines in oncology for colon and rectal cancers recommend FOLFOX as the optimal treatment for patients with unresectable recurrent colon cancer with hepatic metastasis, and systemic chemotherapy with a combination of FOLFIRI and anti-VEGF antibody or anti-EGFR antibody. This evidence concerns the gene EGFR and colorectal cancer.